« BackJournal of the American Academy of Dermatology
Article in Press

Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial

  • Richard G. Langley, MD

      Affiliations

    • Dalhousie Medical School, Halifax, Halifax, Nova Scotia, Canada
    • Corresponding Author InformationReprint requests: Richard G. Langley, MD, Division of Dermatology, Dalhousie University, QE2 Health Science Center, 4195 Dixon Bldg, 5820 University, Halifax, NS, Canada, B3H1V8.
    • ,
  • Amy S. Paller, MD

      Affiliations

    • Children's Memorial Hospital and Northwestern University Medical School, Chicago, Chicago, Illinois
    • ,
  • Adelaide A. Hebert, MD

      Affiliations

    • University of Texas Dermatology Clinical Research Center, Houston, Texas
    • ,
  • Kara Creamer, MS

      Affiliations

    • Amgen Inc, Thousand Oaks, Thousand Oaks, California
    • ,
  • Haoling H. Weng, MD

      Affiliations

    • Amgen Inc, Thousand Oaks, Thousand Oaks, California
    • ,
  • Angelika Jahreis, MD, PhD

      Affiliations

    • Amgen Inc, Thousand Oaks, Thousand Oaks, California
    • ,
  • Denise Globe, PhD

      Affiliations

    • Amgen Inc, Thousand Oaks, Thousand Oaks, California
    • ,
  • Vaishali Patel, PharmD, MS

      Affiliations

    • Amgen Inc, Thousand Oaks, Thousand Oaks, California
    • ,
  • Seth J. Orlow, MD, PhD

      Affiliations

    • New York University Langone Medical Center, New York, New York

Accepted 14 February 2010. published online 09 July 2010.
Corrected Proof

Full Text Available

  • This article may not be purchased.
    Access is limited to print subscribers.

  • Subscribe to this title
  • Claim access now

    Current subscribers


    •  Drs Jahreis and Patel are former employees of Amgen Inc; they are currently employed by Genentech and Allergan, respectively.

     This analysis was designed by Amgen Inc and funded by Immunex Corp, a wholly owned subsidiary of Amgen Inc, and by Wyeth, which was acquired by Pfizer Inc in October 2009. Financial support for the preparation of the manuscript was provided by Amgen Inc.

     Disclosure: Dr Langley has received investigator grants from Amgen, Schering, Abbott, Centocor, LEO Pharma, Novartis, Celgene, Pfizer, NanoBio, Serono, Bristol-Myers Squibb, and Isotechnika, and has received honoraria from serving on the scientific advisory boards for Amgen, Schering, and Abbott. Dr Paller has served as an investigator for Amgen without compensation, but has received honoraria from Amgen and Centocor/Johnson & Johnson as a consultant. Dr Hebert has received compensation from Amgen as a consultant and has served as a researcher for Amgen without compensation. Dr Orlow has been an investigator for Amgen without compensation, but has received honoraria from Amgen and Centocor/Johnson & Johnson as a consultant, and his department has been the recipient of an unrestricted educational grant from Amgen. Ms Creamer and Drs Weng and Globe are Amgen employees and have Amgen stock and stock options. Drs Jahreis and Patel were Amgen employees at the time this manuscript was drafted and held Amgen stock and stock options.

    PII: S0190-9622(10)00365-8

    doi:10.1016/j.jaad.2010.02.060

    « BackJournal of the American Academy of Dermatology